

REMARKS

This Preliminary Amendment is submitted to enter Applicants' claims of priority from corresponding U.S. Patent Application No. 09/734,054 filed October 18, 1996, which in turn claims priority from U.S. Provisional Application No. 60/005,649 filed October 19, 1995. No new matter is added. Entry of this amendment is respectfully requested.

Claim 19 is amended herein to reduce filing fees.

CONCLUSION

If any minor matters remain to be discussed prior to examination, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By William D. Noonan
William D. Noonan, M.D.
Registration No. 30,878

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

20040310 130400

**Marked-up Version of Amended Specification and Claims
Pursuant to 37 C.F.R. §§ 1.121(b)-(c)**

In the specification:

On page 1, after the title, please insert the following new paragraph:

Priority Claim

This is a divisional of U.S. Patent Application No. 09/734,054 filed October 18, 1996, which in turn claims the benefit of U.S. Provisional Application No. 60/005,649 filed October 19, 1995.

In the claims:

Please amend claim 19 as follows:

19. A process for treating a subject which is a human subject or a non-human animal subject in order to achieve expression of a foreign gene in vivo, comprising administering to said subject a pharmaceutical composition according to claim 17 [or to claim 18].

20030701 13:40:00